Leukoencephalopathy with vanishing white matter 1
MONDO:0020507Any leukoencephalopathy with vanishing white matter in which the cause of the disease is a variation in the EIF2B1 gene.
Also known as: CACH, childhood ataxia with central nervous system hypomyelinization, vanishing white matter leukodystrophy, Cree leukoencephalopathy
3 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Last hope drug trial for kids with fatal brain disease
Disease control OngoingThis study gives one child with Cree Leukoencephalopathy (CLE) access to an experimental drug called fosigotifator. CLE is a rare, inherited brain disease that destroys white matter and leads to early death. The drug aims to slow or stop the damage, possibly easing symptoms and i…
Phase: NA • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Desperate patients get early access to experimental brain drug
Disease control NO_LONGER_AVAILABLEThis program offers early access to fosigotifator, an oral drug, for people with Vanishing White Matter or Cree Leukoencephalopathy—two rare, serious brain diseases. A doctor must decide if the potential benefit outweighs the risks for each patient. The drug is not yet approved, …
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Last hope: experimental drug tested in single child with rare brain disease
Disease control OngoingThis study gives one patient with Cree Leukoencephalopathy, a rare and fatal brain disease, access to an experimental drug called fosigotifator. The drug aims to slow or stop the brain damage that causes severe disability and early death. Researchers will track whether the patien…
Phase: EARLY_PHASE1 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC